LONP1 ameliorates liver injury and improves gluconeogenesis dysfunction in acute-on-chronic liver failure

• Published in: Chinese medical journal 2024-01, Vol.137 (2), p.190-199
• Main Authors: Wu, Muchen, Wu, Jing, Liu, Kai, Jiang, Minjie, Xie, Fang, Yin, Xuehong, Wu, Jushan, Meng, Qinghua
• Format: Article
• Language: English
• Subjects: Acute-On-Chronic Liver Failure - pathology; Adenoviruses; Animals; Antibodies; Apoptosis; ATP-Dependent Proteases - metabolism; Biotechnology; Cell culture; Gene expression; Gluconeogenesis; Glucose; Hepatocytes - pathology; Histopathology; Humans; Hypoglycemia; Injuries; Liver - metabolism; Liver cirrhosis; Medical prognosis; Medical research; Metabolism; Mice; Mitochondrial Proteins - metabolism; Morphology; Mortality; Phosphorylation; Protease La - metabolism; Proteins
• ISSN: 0366-6999; 2542-5641
• DOI: 10.1097/CM9.0000000000002969

Acute-on-chronic liver failure (ACLF) is a severe liver disease with complex pathogenesis. Clinical hypoglycemia is common in patients with ACLF and often predicts a worse prognosis. Accumulating evidence suggests that glucose metabolic disturbance, especially gluconeogenesis dysfunction, plays a critical role in the disease progression of ACLF. Lon protease-1 (LONP1) is a novel mediator of energy and glucose metabolism. However, whether gluconeogenesis is a potential mechanism through which LONP1 modulates ACLF remains unknown. In this study, we collected liver tissues from ACLF patients, established an ACLF mouse model with carbon tetrachloride (CCl 4 ), lipopolysaccharide (LPS), and D-galactose (D-gal), and constructed an in vitro hypoxia and hyperammonemia-triggered hepatocyte injury model. LONP1 overexpression and knockdown adenovirus were used to assess the protective effect of LONP1 on liver injury and gluconeogenesis regulation. Liver histopathology, biochemical index, mitochondrial morphology, cell viability and apoptosis, and the expression and activity of key gluconeogenic enzymes were detected to explore the underlying protective mechanisms of LONP1 in ACLF. We found that LONP1 and the expressions of gluconeogenic enzymes were downregulated in clinical ACLF liver tissues. Furthermore, LONP1 overexpression remarkably attenuated liver injury, which was characterized by improved liver histopathological lesions and decreased serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) in ACLF mice. Moreover, mitochondrial morphology was improved upon overexpression of LONP1. Meanwhile, the expression and activity of the key gluconeogenic enzymes were restored by LONP1 overexpression. Similarly, the hepatoprotective effect was also observed in the hepatocyte injury model, as evidenced by improved cell viability, reduced cell apoptosis, and improved gluconeogenesis level and activity, while LONP1 knockdown worsened liver injury and gluconeogenesis disorders. We demonstrated that gluconeogenesis dysfunction exists in ACLF, and LONP1 could ameliorate liver injury and improve gluconeogenic dysfunction, which would provide a promising therapeutic target for patients with ACLF.